NASDAQ
13.05.26 | 21:59
12,580 US-Dollar
+0,16 % +0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.05. | Earnings call transcript: Phathom Pharmaceuticals übertrifft EPS-Erwartungen für Q1 2026 | 6 | Investing.com Deutsch | ||
| 01.05. | Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at DDW 2026 Annual Meeting | 4 | GlobeNewswire (USA) | ||
| 30.04. | Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3 | 1 | Seeking Alpha | ||
| 30.04. | Phathom Q1 2026 slides: revenue doubles, profitability in sight | 4 | Investing.com | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 30.04. | Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript | 4 | Benzinga.com | ||
| 30.04. | Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | 165 | GlobeNewswire (Europe) | ~1.35 million total VOQUEZNA prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2... ► Artikel lesen | |
| 30.04. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.04. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.04. | Phathom Pharmaceuticals Q1 2026 Earnings Preview | 3 | Seeking Alpha | ||
| 20.04. | Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026 | 1 | GlobeNewswire (USA) | ||
| 27.03. | Phathom upgraded at Barclays following pullback, Voquezna optimism | 2 | Seeking Alpha | ||
| 27.03. | Barclays stuft Phathom Pharmaceuticals wegen positiver Umsatzprognose hoch | 3 | Investing.com Deutsch | ||
| 27.03. | Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook | 4 | Investing.com | ||
| 27.02. | Guggenheim raises Phathom stock price target to $25 on revenue beat | 1 | Investing.com | ||
| 26.02. | Phathom outlines $320M-$345M 2026 revenue guidance as company targets operating profitability | 1 | Seeking Alpha | ||
| 26.02. | Stifel reiterates Buy on Phathom stock, keeps $28 price target | 3 | Investing.com | ||
| 26.02. | Phathom Q4 2025 slides: 217% revenue growth, profitability in sight | 3 | Investing.com | ||
| 26.02. | Phathom Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.02. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.01. | Phathom Pharmaceuticals: Stifel bekräftigt "Buy"-Rating nach starkem Umsatzausblick | 7 | Investing.com Deutsch |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,05 | +0,38 % | Alarm bei BioNTech! Milliarden bei Hensoldt! Kaufchance bei North Arrow Minerals! | "Erst kaufen, dann killen", so reagierte Tübingens Oberbürgermeister Boris Palmer auf die geplanten Standortschließungen von BioNTech. Denn in diesem Rahmen sollen praktisch alle Standorte der erst... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,000 | -0,37 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,152 | -0,63 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| KUROS BIOSCIENCES | 22,800 | +0,18 % | Kuros Biosciences AG: Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth | Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Schlieren (Zurich), Switzerland, May 7, 2026 - Kuros... ► Artikel lesen | |
| ABIVAX | 105,80 | +1,93 % | EQS-News: ABIVAX: Abivax Announces Results of its May 11, 2026 Annual General Meeting | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11.05.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| IMMUNITYBIO | 6,850 | -1,58 % | ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum | ||
| MICROBOT MEDICAL | 1,905 | +2,42 % | Microbot Medical Inc. - 10-Q, Quarterly Report | ||
| ATAIBECKLEY | 3,680 | +1,66 % | Trump zündet den Turbo: Warum AtaiBeckley und Emyria jetzt im Fokus der Anleger stehen | ||
| CARDIFF ONCOLOGY | 1,435 | -0,90 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,060 | -2,08 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates | 1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial... ► Artikel lesen | |
| ARGENX | 692,20 | +0,99 % | Muskelschwäche-Medikament Vyvgart treibt Biotechunternehmen Argenx weiter an | AMSTERDAM (dpa-AFX) - Der starke Lauf seines Muskelschwäche-Medikaments Vyvgart hat dem Biotechspezialisten Argenx auch zum Jahresstart Schub verliehen. Der Konzernumsatz - der sich aktuell noch nahezu... ► Artikel lesen | |
| DENALI THERAPEUTICS | 16,450 | -2,78 % | Denali Therapeutics GAAP EPS of -$0.69 | ||
| CYTOKINETICS | 66,10 | +0,24 % | Cytokinetics presents new data on heart drug aficamten | ||
| FATE THERAPEUTICS | 1,644 | -9,87 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | RECLAIM - LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,766 | +6,14 % | Voyager Therapeutics, Inc.: Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 | - VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON... ► Artikel lesen |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,16 % bei einem Aktienkurs von 12,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.